Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Assessment

Samsung Biologics announced on January 29 that it has received the Platinum rating-the highest grade awarded only to the top 1% of companies-in the ESG (Environmental, Social, and Governance) assessment conducted by EcoVadis, a global sustainability evaluation agency.

Founded in France in 2007, EcoVadis annually conducts comprehensive evaluations of over 150,000 companies across 185 countries in four categories: environment, labor and human rights, ethics, and sustainable procurement. Based on these evaluations, it assigns Platinum, Gold, Silver, and Bronze ratings. The EcoVadis ESG assessment is recognized worldwide as a highly reliable supply chain evaluation index. Global pharmaceutical companies such as GlaxoSmithKline (GSK) and AstraZeneca (AZ) are known to use it as a key standard for determining the sustainability of their supply chains.

EcoVadis Platinum Level Badge

Samsung Biologics, which was awarded the Gold rating in 2024, achieved an upgrade to the Platinum rating in the 2025 assessment. The Platinum rating requires a high level of maturity in all aspects, from establishing and implementing ESG policies to performance management and transparent information disclosure, and is granted only to the top 1% of all evaluated companies.

In this assessment, Samsung Biologics was highly rated for its effective ESG management activities across the areas of environment, labor and human rights, ethics, and sustainable procurement. In the environmental category, the company minimized its environmental impact through systematic water management, including wastewater quality assessment and the substitution of hazardous substances. In the labor and human rights category, it operated training systems to foster a safe and fair working environment and to enhance employee capabilities.

In the ethics category, Samsung Biologics advanced ethical management by establishing global-standard ethical management indicators and conducting annual assessments. In the sustainable procurement category, the company strengthened ESG execution capabilities throughout its supply chain by providing carbon neutrality education to its procurement department.

Samsung Biologics Plant 4 exterior view. Samsung Biologics

Meanwhile, Samsung Biologics has taken a leading role in global sustainable management by declaring its "2025 Net-Zero" initiative and joining RE100 (100% renewable energy use) in 2022, as well as chairing the supply chain sector of the UK Royal Family-led Sustainable Markets Initiative (SMI). Notably, in both 2022 and 2025, Samsung Biologics, together with global pharmaceutical companies such as GSK, AZ, and Merck, issued open letters to suppliers, urging active participation in addressing climate change.

John Rim, CEO of Samsung Biologics, stated, "Achieving the Platinum rating once again demonstrates our leadership as an ESG frontrunner in the global pharmaceutical and biopharmaceutical industry. We will continue to fulfill our responsibilities as a trusted CDMO through ESG management that meets the expectations of our customers and stakeholders."

This content was produced with the assistance of AI translation services.